Latest news
FDA Clears IND for RAG-1C saRNA candidate targeting proliferative vitreoretinopathy - Ophthalmology Times EuropeOphthalmology Times Europe · Mon, 03 Aug 2026 19:02:58 GMTRactigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy - The Manila TimesThe Manila Times · Fri, 31 Jul 2026 11:26:59 GMT